Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.54 |
| ▸ | DRD3 | P35462 | 6/20 | 0.52 |
| ▸ | HTR1D | P28221 | 2/20 | 0.52 |
| ▸ | DRD1 | P21728 | 4/20 | 0.49 |
| ▸ | DRD5 | P21918 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30042062 | 0.85 | DRD2 (0.55) | DRD2DRD3HTR1DDRD1DRD5 | |
| SCHEMBL19599368 | 0.84 | DRD2 (0.47) | DRD2DRD3HTR1DDRD1DRD5 | |
| SCHEMBL506173 | 0.83 | DRD2 (0.45) | DRD2DRD3HTR1DDRD1DRD5 | |
| SCHEMBL1820878 | 0.82 | DRD2 (0.53) | DRD2DRD3HTR1DDRD1DRD5 | |
| SCHEMBL3113928 | 0.82 | DRD2 (0.53) | DRD2DRD3HTR1DDRD1DRD5 | |
| SCHEMBL506250 | 0.82 | DRD2 (0.47) | DRD2DRD3HTR1DDRD1DRD5 | |
| SCHEMBL2589591 | 0.79 | DRD2 (0.50) | DRD2DRD3HTR1DDRD1DRD5 | |
| SCHEMBL20573750 | 0.79 | S1PR5 (0.53) | DRD2DRD3HTR1DDRD1DRD5 | |
| SCHEMBL16518064 | 0.78 | DRD2 (0.47) | DRD2DRD3HTR1DDRD1DRD5 | |
| SCHEMBL11960176 | 0.77 | DRD2 (0.48) | DRD2DRD3HTR1DDRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327493-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327493-A1 | CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, CXCR2 | DRD2 684/4885DRD3 665/4885HTR1D 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.